Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
USEI : go here http://www.usenergyic.com/index.php?option=com_content&task=view&id=41&Itemid=37 and look at their patented dual fuel technology
Dual Fuel
Patent Dual-Fuel Diesel To Natural
Gas Conversion Technology
Dual-fuel system for use on medium
and heavy-duty engines.
Operates on diesel and natural gas.
System Overview and Benefits
Available for medium-and heavy-duty diesel engines (including off-road).
Available for stationary engines.
Operates on Compressed Natural Gas (CNG) or Liquefied Natural Gas (LNG) and Diesel.
Patented, breakthrough technology in a digital system. This is the most cost-effective solution to reduce pollutants while still retaining the original power and performance of the engine.
Only product on the market universally adaptable to virtually any diesel engine through software programming -no engine modifications required.
Up to 80% displacement of diesel fuel.
Approximately 1/3 the cost of an engine repower.
Reduce NOx emissions by at least 23%
Custom-designed fuel storage systems meet all regulatory safety requirements.
Used on new or existing vehicles.
Operation can return to diesel-fuel only mode at any time by a flip of a switch
--------------------------------------------------------------------------------
Our Technology
2 Hybrid-Certified mechanics
one-day installation
Hardware is a generic bolt-on system
No engine modifications
Can be mounted to the frame, body or engine
Mounted with four allen head bolts
USEI in at 0.1021. Go look it up yourself. Will be running HOD soon
US Energy Enters Agreement Granting Exclusive Domestic U.S. Rights to BAF Technologies
Partnership Will Also Join Forces to Gain CARB Tier III Certification as Emission Control Device
US Energy Initiatives Corporation ("US Energy" or the "Company") (OTCBB: USEI), an ISO-9001 certified manufacturer of a patent dual-fuel system (the "Hybrid System") today announced an agreement in principal with BAF Technologies ("BAF") to grant exclusivity for portions of the domestic United States for sales of the Company's patent dual-fuel diesel to natural gas technology. In addition, USEI will join its Hybrid System together with BAF's SmartMuffler technology in a program to achieve a California Air Resource Board (CARB) Tier III Certification as an emission control device.
"This agreement with BAF marks our first major domestic US push to deploy our technology," said USEI CEO Mark Clancy. "We have enjoyed a long and rewarding relationship with BAF for several years and it is a pleasure to expand our business relationship. Our Chief Operating Officer Phil Rappa negotiated the general terms of our agreement underwhich we will be granting BAF exclusive rights for the Southwestern US including California and Northeastern US including New York. To start the program, BAF will be providing two Cummins engines which will be converted with USEI's dual fuel system and BAF's SmartMuffler technology. It is our common objective to achieve a CARB Tier III certification for this configuration which will make our system available for sale anywhere within the United States. While we are excited about our many advances in deploying our technology in the international marketplace, this represents the first and best opportunity to match our foreign activity with a strong domestic program," concluded Mr. Clancy.
"BAF is excited to enter into a new phase of our relationship with USEI," says John Bacon, BAF's president. "We have each been pushing the industry forward as we have continued to innovate, and this deeper relationship will continue that tradition. With exclusivity in the northeast and southwest including California, we will be able to focus on key, growing markets. Of particular interest are the ports of California which have been allocated more than $2B to improve air quality. A major focus of which addresses the more than 2300 off road yard trucks which are all viable targets for this dual-fuel system. The opportunity is tremendous."
About US Energy Initiatives Corporation (OTCBB: USEI)
US Energy, formed in 1996, commercializes a patent dual-fuel diesel to natural gas conversion technology through the automotive aftermarket and through certain original equipment manufacturers. The Company's facilities include a state-of-the-art systems development and testing lab in PeachTree City, Georgia and an ISO-9001 certified manufacturing facility in Tampa, Florida.
About BAF Technologies
BAF Technologies is the premier provider of natural gas and propane vehicle conversions. Founded in 1992, and headquartered in Dallas, Texas, the company supports global clients with alternative fuel systems (both LPG and CNG), application engineering, technical training, service parts, technical consulting, research and development, design, and engineered products. During the past decade, the company has been the leader in marketing and systems integration for niche markets within the Alternative Fuel Vehicle (AFV) industry.
LSKA a great find....listen to me this time at least
I got in at 0.09
Look at their PRs and do ur DD.
This is a gem
USEI ALERT ALERT ....REVERSAL in PROGRESS
Their hybrid tech will be bought out. Great at these levels.
NEP last chance at 2.30..see ya all at 3.00
they were approved for a human trial by FDA
I found this great article on HF
Artif Organs. 2006 Aug;30(8):579-85.
Online hemodiafiltration.Van Laecke S, De Wilde K, Vanholder R.
Nephrology Section of Department of Internal Medicine, University of Ghent, De Pintelaan 185, Ghent, Belgium.
Online hemodiafiltration (HDF) is an extracorporeal technique for solute removal in renal failure, which takes advantage of an enhancement of convective treatment by the large amount of ultrapure nonpyrogen dialysate being used for substitution of the ultrafiltered volume. It offers many advantages aside from its safe inflammatory profile, which is attributable to the use of ultrapure dialysate and highly biocompatible dialysis membranes. Due to an improved convective clearance, significantly increased removal of large or protein-bound uremic retention solutes can be achieved, with a potential benefit on cardiovascular morbidity and mortality. Recent observational data indicate that online HDF offers a survival advantage even after adjustment for comorbidity and dialysis efficiency. Research has been ongoing to maximize further the effectiveness of the technique by new technical innovations such as transmembrane-pressure feedback control or mid-dilution online HDF.
NEP especially for my CASH COW friends...
NEP is approved for a human trial by FDA
I found this great article on HF
Artif Organs. 2006 Aug;30(8):579-85.
Online hemodiafiltration.Van Laecke S, De Wilde K, Vanholder R.
Nephrology Section of Department of Internal Medicine, University of Ghent, De Pintelaan 185, Ghent, Belgium.
Online hemodiafiltration (HDF) is an extracorporeal technique for solute removal in renal failure, which takes advantage of an enhancement of convective treatment by the large amount of ultrapure nonpyrogen dialysate being used for substitution of the ultrafiltered volume. It offers many advantages aside from its safe inflammatory profile, which is attributable to the use of ultrapure dialysate and highly biocompatible dialysis membranes. Due to an improved convective clearance, significantly increased removal of large or protein-bound uremic retention solutes can be achieved, with a potential benefit on cardiovascular morbidity and mortality. Recent observational data indicate that online HDF offers a survival advantage even after adjustment for comorbidity and dialysis efficiency. Research has been ongoing to maximize further the effectiveness of the technique by new technical innovations such as transmembrane-pressure feedback control or mid-dilution online HDF.
NEP is moving so fast my head is spinning
they were approved for a human trial by FDA
I found this great article on HF
Artif Organs. 2006 Aug;30(8):579-85.
Online hemodiafiltration.Van Laecke S, De Wilde K, Vanholder R.
Nephrology Section of Department of Internal Medicine, University of Ghent, De Pintelaan 185, Ghent, Belgium.
Online hemodiafiltration (HDF) is an extracorporeal technique for solute removal in renal failure, which takes advantage of an enhancement of convective treatment by the large amount of ultrapure nonpyrogen dialysate being used for substitution of the ultrafiltered volume. It offers many advantages aside from its safe inflammatory profile, which is attributable to the use of ultrapure dialysate and highly biocompatible dialysis membranes. Due to an improved convective clearance, significantly increased removal of large or protein-bound uremic retention solutes can be achieved, with a potential benefit on cardiovascular morbidity and mortality. Recent observational data indicate that online HDF offers a survival advantage even after adjustment for comorbidity and dialysis efficiency. Research has been ongoing to maximize further the effectiveness of the technique by new technical innovations such as transmembrane-pressure feedback control or mid-dilution online HDF.
NEP get ready for some action guys
NEW YORK, Jan 29, 2007 (BUSINESS WIRE) -- Nephros, Inc. (AMEX:NEP) today reported that the Company received conditional approval for its Investigational Device Exemption (IDE) application from the Food and Drug Administration (FDA) to begin a human clinical trial of the Company's OLpur(TM) H2H(TM) Hemodiafiltration Module and OLpur(TM) MD 220 Hemodiafilter. Nephros has been granted this approval on the condition that, by March 5, 2007, it will submit a response to two informational questions from the FDA. The Company has already provided a partial response to these questions.
Nephros is also required to obtain approval from one or more Institutional Review Boards (IRBs) in order to proceed with its clinical trial. Nephros is in the process of seeking approvals from the relevant IRBs.
Nephros plans to conduct the trial at three clinics in the Greater New York area:
--Columbia University Dialysis Center (Dr. Anthony Valeri, M.D., Associate Professor of Clinical Medicine, Columbia University, College of Physicians & Surgeons, NY, site principal investigator);
--Bronx Dialysis Center (Dr. Robert Lynn, M.D., Clinical Associate Professor of Medicine, Albert Einstein College of Medicine, site principal investigator); and
--DCI, North Brunswick, New Jersey (Dr. Toros Kapoian M.D., FACP, Associate Professor of Medicine, Robert Wood Johnson Medical School, site principal investigator).
Columbia University Dialysis Center and Bronx Dialysis Center are affiliated with or managed by DaVita, Inc. and DCI is affiliated with or managed by Dialysis Clinic, Inc.
Dr. Leonard Stern, M.D., FACP, FASN, who is an Associate Professor of Clinical Medicine at Columbia University, College of Physicians & Surgeons in New York, will act as Coordinating Principal Investigator during the trial.
Nephros and Dr. Stern anticipate that the introduction of online hemodiafiltration (HDF) into the clinical arena for dialysis-dependent patients will provide a significant improvement in dialysis care compared to conventional hemodialysis. They also believe that this new treatment method offers the promise of improving the quality of life for this chronically ill group, while reducing both morbidity and mortality.
Dr. Kapoian from DCI stated, "Since the 1970's, we have not seen substantial advances in the actual dialysis process here in the U.S. I believe this is an exciting opportunity to explore a new therapy for End-Stage Renal Disease patients in the United States that may have a positive impact on patient care."
Norman Barta, President and Chief Executive Officer of Nephros, commented, "This FDA action is a critical step forward for Nephros, allowing us to proceed with clinical trials on our MD and H2H technologies. There is a growing body of evidence supporting the benefits of hemodiafiltration therapy over hemodialysis therapy. Furthermore, studies in Europe have demonstrated the superiority of Nephros' mid-dilution therapy over existing hemodialysis and HDF therapies with respect to certain measures of performance. We believe that, upon its approval, Nephros' technology will be a vitally important addition to the physician's arsenal in treating patients with End-Stage Renal Disease, providing potentially substantial reductions in patient morbidity, mortality, and overall treatment costs."
Nephros Mid-Dilution Technology:
Hemodiafiltration is an accepted therapy practiced widely in Europe, where HDF machines are available. HDF is a convective-based renal replacement therapy, whereby a negative pressure (similar to a vacuum effect) is applied to draw plasma water and additional toxins from the blood as it passes by the hemodialyzer membrane. In HDF, this convective process takes place at the same time that toxins are removed by diffusion, which is the basis of hemodialysis, the renal replacement therapy commonly practiced in the United States. By combining diffusion with convection, HDF offers efficient removal of small solutes by diffusion, while providing improved removal of larger substances (i.e., middle molecules) by convection. Nephros has patented technology relating to a design and process called Mid-Dilution Diafiltration, or MDF. MDF is a fluid management system that optimizes the removal of both small toxins and middle-molecules by offering the advantages of pre-dilution HDF and post-dilution HDF combined in a single dialyzer cartridge. Nephros has demonstrated through clinical trials in Europe that the MDF process provides improved removal of certain toxins in HDF treatments, and believes this will result in improved patient health and a concurrent reduction in healthcare costs.
Nephros believes that its OLpur(TM) MDHDF filter series (including the OLpur(TM) MD220) are the only filters designed specifically for HDF and offer superior toxin clearance as well as improved performance over conventional hemodialyzers. The Nephros OLpur(TM) MDHDF filter series, having received CE Marking in Europe, is in clinical use in 12 European countries.
The OLpur(TM) H2H offers clinics a simple way to upgrade hemodialysis therapy to HDF therapy without incurring the costs and inconveniences generally associated with HDF machines. The OLpur(TM) H2H is an add-on module that converts the most common types of hemodialysis machines into HDF-capable machines. As a result, clinics using the OLpur(TM) H2H will be able to introduce patients to HDF therapy without replacing an existing dialysis machine base or incurring large machine-replacement costs.
Commenting on the IDE approval, William Fox, Executive Chairman of Nephros, said, "According to industry sources, the number of End-Stage Renal Disease patients worldwide is expected to grow approximately 50% to 2.4 million by 2010. Our MD blood filter, already being utilized in over 50 clinics in Europe, offers both clinical and economic advantages over conventional dialysis treatment. Studies of HDF therapy have shown reductions of up to 35% in mortality risk, substantial drug reductions, fewer hospitalizations and reduced infection risks for patients. At the same time, once our H2H Module for HD machines is approved, hospitals and clinics will be able to make the transition to Hemodiafiltration MDF therapy, while still using their existing dialysis machines. We are excited about the opportunity to bring Nephros' MDF innovation to the United States."
Trial:
The proposed trial is designed to assess the safety and efficacy of the Nephros OLpur(TM) H2H Module and the Nephros MD 220 Hemodiafilter devices, which have been developed to enable online HDF to be performed with a conventional ultrafiltration controlled hemodialysis machine. Online HDF is a "convective" based renal replacement therapy offering improved removal of uremic toxins, in particular middle-molecular weight toxins such as beta-2-microglobulin (b2m). The trial is a prospective, multi-center trial whereby stable End-Stage Renal Disease patients will be monitored during a first hemodialysis (control) period using their current hemodialysis machine with a conventional high-flux dialyzer, followed by a second hemodiafiltration (test) period using their current hemodialysis machine, the Nephros H2H Module, and the Nephros MD 220 Hemodiafilter. During the trial, the occurrence of adverse events and adverse symptoms will be recorded as primary study endpoints, while blood chemistries (including b2m and C-reactive protein) and quality of the online infusion fluid will be measured as secondary endpoints. In addition, patients will fill out a quality of life survey at the end of each study period as a means to assess if they are feeling better on either of the two treatments methods. Upon successful completion of the trial, the Company plans to seek FDA approval to market both the H2H Module and the MD 220 Hemodiafilter. The Company currently anticipates seeking such approval in early 2008.
About Nephros Inc.
Nephros, Inc., headquartered in New York, is a medical device company developing and marketing products designed to improve the quality of life for the End-Stage Renal Disease (ESRD) patient, while addressing the critical financial and clinical needs of the care provider. ESRD is a disease state characterized by the irreversible loss of kidney function. Nephros believes that its products, particularly its Mid-Dilution Hemodiafiltration therapy, are designed to remove a range of harmful substances more effectively, and more cost-effectively, than existing ESRD treatment methods; particularly with respect to substances known collectively as "middle molecules," due to their molecular weight, that have been found to contribute to such conditions as dialysis-related amyloidosis, carpal tunnel syndrome, degenerative bone disease and, ultimately, mortality in the ESRD patient. Nephros products are currently being used in over fifty clinics in Europe, and are distributed by Bellco SpA in Italy, France and Belgium.
Nephros also markets a line of water filtration products, the Dual Stage Ultrafilter (DSU). The Company's patented dual stage cold sterilization ultrafilter has the capability to filter out bacteria and, due to its exceptional filtration levels, filter out many viruses and parasites. The DSU proprietary design provides dual-stage filtration reducing the risk of filtration failure. With initial focus on health care, the DSU is in a pilot-use program at a major medical center and has been selected for further development by the US Marine Corps. The Company considers the DSU a significant breakthrough in providing affordable and reliable water filtration. The DSU is based on Nephros' proprietary water filtration technology originally designed for medical use in its H2H machine, and is a complimentary product line to the Company's main focus, the End Stage Renal Disease therapy business.
For more information on Nephros please visit the Company's website, www.nephros.com.
Amazing action. Loving every second of this.
SGN shakerzzzz... BHAGIRA PLAY...Makes cardiac monitoring easy...
HUGE VOLUME
January 26, 2007 - 11:30 AM EST
close Email this News Article
Your Name
Your Email
Friend's Name
Friend's Email
Receive Copy: yes
SGN 1.92 0.0398
Today 5d 1m 3m 1y 5y 10y
Signalife Completes Prototype of Arbitrary Waveform Generator for Intracardiac and Electrogram Recordings
GREENVILLE, S.C., Jan. 26 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN) Signalife, Inc. announced that it has completed the development of a prototype device to be utilized for objective evaluation of ECG/IC (Electrocardiogram and Intracardiac) data Recorders. This device will be utilized to provide industry with an objective measurement of an ECG systems ability to precisely measure the electrical activity of the heart. This mechanism for evaluating all ECG systems will provide physicians, hospitals, and other end users with valuable information regarding the clinical efficacy of various ECG systems across the market which will allow them to better evaluate their future purchasing decisions.
Dr. Budimir S. Drakulic, the inventor of the company's technologies and its Chief Technology Officer, stated: 'We are very excited to develop this unique device. From the Company's inception, our intent was to objectively evaluate our patented signal processing technology against other competitive devices on the market. A new arbitrary waveform generator for Intracardiac and surface Electrocardiographic signals will allow objective evaluation of recording systems in their ability to faithfully reproduce the ECG/IC signal. This new device will generate wave shapes that the investigator determines are important for specific evaluation and comparison across the industry. Some of the data comparison was reported during the Heart Rhythm Society Meeting at Boston in May of 2006, and we intend to publish additional findings in various clinical journals.'
The objective valuation of ECG technologies permitted by the use of the Signalife simulator reveals what the R&D staff has exerted and what members of the medical community have underscored in terms of -- once and for all -- getting to the bottom of cardiovascular disease and its costs and injury to our society every year.
About Signalife
Signalife, Inc, is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.
Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.
There was some resistance at 1.94 as stockdoctor said. But looks like its making round#2 here after this PR
January 26, 2007 - 11:30 AM EST
close Email this News Article
Your Name
Your Email
Friend's Name
Friend's Email
Receive Copy: yes
SGN 1.92 0.0398
Today 5d 1m 3m 1y 5y 10y
Signalife Completes Prototype of Arbitrary Waveform Generator for Intracardiac and Electrogram Recordings
GREENVILLE, S.C., Jan. 26 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN) Signalife, Inc. announced that it has completed the development of a prototype device to be utilized for objective evaluation of ECG/IC (Electrocardiogram and Intracardiac) data Recorders. This device will be utilized to provide industry with an objective measurement of an ECG systems ability to precisely measure the electrical activity of the heart. This mechanism for evaluating all ECG systems will provide physicians, hospitals, and other end users with valuable information regarding the clinical efficacy of various ECG systems across the market which will allow them to better evaluate their future purchasing decisions.
Dr. Budimir S. Drakulic, the inventor of the company's technologies and its Chief Technology Officer, stated: 'We are very excited to develop this unique device. From the Company's inception, our intent was to objectively evaluate our patented signal processing technology against other competitive devices on the market. A new arbitrary waveform generator for Intracardiac and surface Electrocardiographic signals will allow objective evaluation of recording systems in their ability to faithfully reproduce the ECG/IC signal. This new device will generate wave shapes that the investigator determines are important for specific evaluation and comparison across the industry. Some of the data comparison was reported during the Heart Rhythm Society Meeting at Boston in May of 2006, and we intend to publish additional findings in various clinical journals.'
The objective valuation of ECG technologies permitted by the use of the Signalife simulator reveals what the R&D staff has exerted and what members of the medical community have underscored in terms of -- once and for all -- getting to the bottom of cardiovascular disease and its costs and injury to our society every year.
About Signalife
Signalife, Inc, is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.
Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.
SGN another good news out..Again below 1.90 ..may be last time
January 26, 2007 - 11:30 AM EST
close Email this News Article
Your Name
Your Email
Friend's Name
Friend's Email
Receive Copy: yes
SGN 1.92 0.0398
Today 5d 1m 3m 1y 5y 10y
Signalife Completes Prototype of Arbitrary Waveform Generator for Intracardiac and Electrogram Recordings
GREENVILLE, S.C., Jan. 26 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN) Signalife, Inc. announced that it has completed the development of a prototype device to be utilized for objective evaluation of ECG/IC (Electrocardiogram and Intracardiac) data Recorders. This device will be utilized to provide industry with an objective measurement of an ECG systems ability to precisely measure the electrical activity of the heart. This mechanism for evaluating all ECG systems will provide physicians, hospitals, and other end users with valuable information regarding the clinical efficacy of various ECG systems across the market which will allow them to better evaluate their future purchasing decisions.
Dr. Budimir S. Drakulic, the inventor of the company's technologies and its Chief Technology Officer, stated: 'We are very excited to develop this unique device. From the Company's inception, our intent was to objectively evaluate our patented signal processing technology against other competitive devices on the market. A new arbitrary waveform generator for Intracardiac and surface Electrocardiographic signals will allow objective evaluation of recording systems in their ability to faithfully reproduce the ECG/IC signal. This new device will generate wave shapes that the investigator determines are important for specific evaluation and comparison across the industry. Some of the data comparison was reported during the Heart Rhythm Society Meeting at Boston in May of 2006, and we intend to publish additional findings in various clinical journals.'
The objective valuation of ECG technologies permitted by the use of the Signalife simulator reveals what the R&D staff has exerted and what members of the medical community have underscored in terms of -- once and for all -- getting to the bottom of cardiovascular disease and its costs and injury to our society every year.
About Signalife
Signalife, Inc, is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.
Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.
SGN ...now 1.94. Stockdoctor said if this crosses 1.94, it wont stop
SGN...I have been flagging this one since 1.77 when I got in. Now its trading at 1.91
Visit this yourself www.signalife.com
They have developed this cardiac monitor which will be a BIG news this year and this company will be bought out soon
SGN ..I have been telling you all week. Huge Volume amazing product. Might be bought out by GE.
Go and do ur DD
www.signalife.com
SGN www.signalife.com Say good bye to $2 today
SGN last chance..1.84 now www.signalife.com
SGN will be $2 tomorrow. Now only 1.85
www.signalife.com
They are making cardiac monitoring very easy and it will be bought out by some BIG company soon
Guys look at SGN www.signalife.com moving like crazzzy
Woo SGN just jumped from 1.77 to 1.85 for me
www.signalife.com
Are guys listening to mee..SGN is moving fast
SGN moved from 1.77 to 1.84 in last 20 min guys www.signalife.com
SGN moving guys
PRH is introduced a BAZI http://www.drinkbazi.biz
This is going to be big cause they have this package for small bussinesses ...they can put this up for sale in their small shops all be themselves.
I got into the stock after drinking this at my GYM and thinking who is making this one.
Well do ur own DD
OPBL moving again..Just got an intraday BUY signal on my software
Does OPBL qualify for this Board. You guys should see this one. 19% shares are bought by NY merch Index.
I cant believe no one is talking ab OPBL
The NY merch index bought 19% of the shares and this one is flyying high on large volume.
With every dip large buying coming in from INstitutional Investors
SGN is back below 1.80, I dont know how long. http://www.signalife.com
They will report earnings soon and that would the end of below $2 trading.
I just got filled for 2000 more shares at 1.77.
I think thats a blessing
Where did u get that short numbers.
I really like this company and looks like a year from now you guys would look back and think you made a mistake by selling this one.
Keep it in your IRA portfolio
http://www.signalife.com SGN is dirt cheap today.
Last time may be
SGN is dirt cheap right now..Go to http://www.signalife.com
BANY news coming tomorrow..HUGE volume
BANY is going crazzyy...HUGE volume
SGN last time below 1.90...soon will fly of the roof
BANy 200 share block traded.. U know what it means..
200 > I need shares badly but dont take it down to get em
BANY 200 shares traded...U know what it means
200 > I need shares badly but dont take it down to get em
SGN last chace to BUY ...It will hit $2 soon
BANY in breakout guys....Last chace below 0.003
BANY breaking out guys...This time it will hit a penny
BANY breaking